Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required

The contract aims to fund clinical trials focused on evaluating the efficacy and safety of treatments for rare neurodegenerative diseases in both children and adults, with the goal of supporting new indications or labeling changes that address significant unmet medical needs. By promoting collaborative, efficient, and innovative trial designs, the FDA seeks to accelerate the approval of new therapies and strengthen the overall landscape of drug development for these rare conditions. The initiative is designed to increase the number of approved treatments and create a broader positive impact on the field of rare disease therapeutics. Funded under the R01 mechanism, this opportunity is open to researchers and institutions conducting clinical trials that meet the specified objectives. The award is managed by the Food and Drug Administration within the Department of Health and Human Services, with Terrin Brown designated as the primary point of contact for grant-related inquiries. The opportunity was posted on August 14, 2024, and while no solicitation number or set-aside details are provided, the effort is part of a broader strategy to improve outcomes for patients affected by rare neurodegenerative disorders through targeted research funding.